Genomic Grade Index predicts postoperative clinical outcome of GIST.
Authors
Bertucci F, Finetti P, Ostrowski J, Kim WK, Kim H, Pantaleo MA, Astolfi A, Polkowski M, Birnbaum D
Summary
Prognosis of localised gastrointestinal stromal tumour (GIST) is heterogeneous, notably for patients with AFIP intermediate or high risk of relapse, who are candidates to adjuvant imatinib. We hypothesised that gene expression profiles might improve the prognostication and help to refine the indications for imatinib.
Read the article